Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTO-203 in Major Depressive Disorder
NCT06391593Phase 2Completed
- Sponsor
- Alto Neuroscience
- Start
- Mar 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alto-203 in major depressive disorder (MDD) and anhedonia ((none)) (3 arms), sponsored by Alto Neuroscience. Primary endpoints: Bond-Lader Visual Analog Scale at 5 hours and Treatment-Emergent Adverse Events. Started Mar 2024; status: completed.
02
Drugs
alto-203
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on NCT06391593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391593.